Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan, and Southeast Asia

0
48
Incyte and China Medical System Holdings Limited (CMS) announced their collaboration and license agreement for the development and commercialization of povorcitinib, a selective oral JAK1 inhibitor. CMS will receive a license to manufacture povorcitinib in inflammatory dermatologic diseases, including non-segmental vitiligo, hidradenitis suppurativa, prurigo nodularis, and chronic spontaneous urticaria.
[Incyte Corporation]
Press Release